Jorgensen Andrea L, Korver Samantha, Schofield Amy, Howell Lawrence, Clarke Joanna I, Walker Lauren E, Brillant Nathalie, Goldring Chris E P, Pirmohamed Munir
Department of Health Data Science, Institute of Population Health, University of Liverpool, Liverpool, UK.
Centre for Drug Safety Science, Department of Pharmacology and Therapeutics, Molecular & Clinical Pharmacology, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.
Br J Clin Pharmacol. 2025 May;91(5):1361-1369. doi: 10.1111/bcp.16371. Epub 2024 Dec 15.
The potential of mechanistic biomarkers to improve prediction of drug-induced liver injury (DILI) and hepatic regeneration is widely acknowledged. We sought to determine reference intervals for new biomarkers of DILI and regeneration, as well as to characterize their natural variability and impact of diurnal variation.
Serum samples from 227 healthy volunteers were recruited as part of a cross-sectional study; of these, 25 subjects had weekly serial sampling over 3 weeks, while 23 had intensive blood sampling over a 24h period. Alanine aminotransferase (ALT), MicroRNA-122 (miR-122), High Mobility Group Box-1 (HMGB1), total Keratin-18 (K18), caspase-cleaved Keratin-18 (ccK18), Glutamate Dehydrogenase (GLDH) and Macrophage Colony-Stimulating Factor-1 (CSF-1) were assayed.
Reference intervals were established for each biomarker based on the 97.5% quantile (90% CI) following the assessment of fixed effects in univariate and multivariable models. Intra-individual variability was found to be non-significant, and there was no significant impact of diurnal variation.
Reference intervals for novel DILI biomarkers have been described. An upper limit of a reference range might represent the most appropriate mechanism to utilize these data. These data can now be used to interpret data from exploratory clinical DILI studies and to assist their further qualification as required by regulatory authorities.
机制性生物标志物在改善药物性肝损伤(DILI)和肝再生预测方面的潜力已得到广泛认可。我们试图确定DILI和再生新生物标志物的参考区间,并描述其固有变异性和昼夜变化的影响。
招募227名健康志愿者的血清样本作为横断面研究的一部分;其中,25名受试者在3周内每周进行系列采样,而23名受试者在24小时内进行密集采血。检测了丙氨酸转氨酶(ALT)、微小RNA-122(miR-122)、高迁移率族蛋白B1(HMGB1)、总角蛋白-18(K18)、半胱天冬酶切割角蛋白-18(ccK18)、谷氨酸脱氢酶(GLDH)和巨噬细胞集落刺激因子-1(CSF-1)。
在单变量和多变量模型中评估固定效应后,基于第97.5百分位数(90%置信区间)为每个生物标志物建立了参考区间。发现个体内变异性不显著,昼夜变化也无显著影响。
已描述了新型DILI生物标志物的参考区间。参考范围的上限可能是利用这些数据的最合适机制。这些数据现在可用于解释探索性临床DILI研究的数据,并根据监管机构的要求协助对其进行进一步验证。